IL2 and acute myeloid leukemia: In the 0201 phase III trial, patients receiving HDC/IL-2 with normal karyotype or chemosensitive AML only rarely relapsed >12 months after random assignment suggesting durable protection against relapse.18,19 The exploratory nature of these posthoc analyses should be emphasized, and further studies are required to define the efficacy of HDC/IL-2 in molecular and other subgroups of AML.